Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-analysis of randomized controlled trials

P. Guedeney, V. Roule, J. Mesnier, C. Chapelle, JJ. Portal, S. Laporte, E. Ollier, M. Zeitouni, M. Kerneis, N. Procopi, O. Barthelemy, S. Sorrentino, M. Mihalovic, J. Silvain, E. Vicaut, G. Montalescot, JP. Collet

. 2023 ; 9 (3) : 251-261. [pub] 2023Apr10

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu metaanalýza, systematický přehled, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010464

AIMS: As the antithrombotic regimen that may best prevent ischaemic complications along with the lowest bleeding risk offset following transcatheter aortic valve implantation (TAVI) remains unclear, we aimed to compare the safety and efficacy of antithrombotic regimens in patients without having an indication for chronic oral anticoagulation. METHODS AND RESULTS: We conducted a PROSPERO-registered (CRD42021247924) systematic review and network meta-analysis of randomized controlled trials evaluating post-TAVI antithrombotic regimens up to April 2022. We estimated the relative risk (RR) and 95% confidence intervals (95% CIs) using a random-effects model in a frequentist pairwise and network metanalytic approach. We included seven studies comprising 4006 patients with a mean weighted follow-up of 12.9 months. Risk of all-cause death was significantly reduced with dual antiplatelet therapy (DAPT) compared with low-dose rivaroxaban + 3-month single antiplatelet therapy (SAPT) (RR 0.60, 95% CI 0.41-0.88), while no significant reduction was observed with SAPT vs. DAPT (RR 1.02, 95% CI 0.67-1.58) and SAPT and DAPT compared with apixaban or edoxaban (RR 0.60, 95% CI 0.32-1.14 and RR 0.59, 95% CI 0.34-1.02, respectively). SAPT was associated with a significant reduction of life-threatening, disabling, or major bleeding compared with DAPT (RR 0.45, 95% CI 0.29-0.70), apixaban or edoxaban alone (RR 0.45, 95% CI 0.25-0.79), and low-dose rivaroxaban + 3-month SAPT (RR 0.30, 95% CI 0.16-0.57). There were no differences between the various regimens with respect to myocardial infarction, stroke, or systemic embolism. CONCLUSION: Following TAVI in patients without an indication for chronic oral anticoagulant, SAPT more than halved the risk of bleeding compared with DAPT and direct oral anticoagulant-based regimens without significant ischaemic offset.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010464
003      
CZ-PrNML
005      
20230801132437.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ehjcvp/pvad003 $2 doi
035    __
$a (PubMed)36640149
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Guedeney, Paul $u Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire, Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, Paris 75013, France
245    10
$a Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-analysis of randomized controlled trials / $c P. Guedeney, V. Roule, J. Mesnier, C. Chapelle, JJ. Portal, S. Laporte, E. Ollier, M. Zeitouni, M. Kerneis, N. Procopi, O. Barthelemy, S. Sorrentino, M. Mihalovic, J. Silvain, E. Vicaut, G. Montalescot, JP. Collet
520    9_
$a AIMS: As the antithrombotic regimen that may best prevent ischaemic complications along with the lowest bleeding risk offset following transcatheter aortic valve implantation (TAVI) remains unclear, we aimed to compare the safety and efficacy of antithrombotic regimens in patients without having an indication for chronic oral anticoagulation. METHODS AND RESULTS: We conducted a PROSPERO-registered (CRD42021247924) systematic review and network meta-analysis of randomized controlled trials evaluating post-TAVI antithrombotic regimens up to April 2022. We estimated the relative risk (RR) and 95% confidence intervals (95% CIs) using a random-effects model in a frequentist pairwise and network metanalytic approach. We included seven studies comprising 4006 patients with a mean weighted follow-up of 12.9 months. Risk of all-cause death was significantly reduced with dual antiplatelet therapy (DAPT) compared with low-dose rivaroxaban + 3-month single antiplatelet therapy (SAPT) (RR 0.60, 95% CI 0.41-0.88), while no significant reduction was observed with SAPT vs. DAPT (RR 1.02, 95% CI 0.67-1.58) and SAPT and DAPT compared with apixaban or edoxaban (RR 0.60, 95% CI 0.32-1.14 and RR 0.59, 95% CI 0.34-1.02, respectively). SAPT was associated with a significant reduction of life-threatening, disabling, or major bleeding compared with DAPT (RR 0.45, 95% CI 0.29-0.70), apixaban or edoxaban alone (RR 0.45, 95% CI 0.25-0.79), and low-dose rivaroxaban + 3-month SAPT (RR 0.30, 95% CI 0.16-0.57). There were no differences between the various regimens with respect to myocardial infarction, stroke, or systemic embolism. CONCLUSION: Following TAVI in patients without an indication for chronic oral anticoagulant, SAPT more than halved the risk of bleeding compared with DAPT and direct oral anticoagulant-based regimens without significant ischaemic offset.
650    _2
$a lidé $7 D006801
650    12
$a inhibitory agregace trombocytů $7 D010975
650    12
$a transkatetrální implantace aortální chlopně $x škodlivé účinky $7 D065467
650    _2
$a fibrinolytika $x terapeutické užití $7 D005343
650    _2
$a rivaroxaban $7 D000069552
650    _2
$a síťová metaanalýza $7 D000071076
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a krvácení $x chemicky indukované $7 D006470
650    _2
$a antikoagulancia $x škodlivé účinky $7 D000925
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Roule, Vincent $u Service de Cardiologie, Centre Hospitalier Universitaire (CHU) de Caen Normandie, Normandie Univ, UMR_S 1166, Caen, France
700    1_
$a Mesnier, Jules $u French Alliance for Cardiovascular Trials (FACT), Université de Paris, INSERM Unité-1148, and Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
700    1_
$a Chapelle, Celine $u Unité de Recherche Clinique, Innovation et Pharmacologie, CHU de Saint-Etienne, Saint-Etienne, France
700    1_
$a Portal, Jean-Jacques $u Unité de Recherche Clinique, Lariboisière Hospital (AP-HP), ACTION Study Group, Paris, France
700    1_
$a Laporte, Silvy $u Unité de Recherche Clinique, Innovation et Pharmacologie, CHU de Saint-Etienne, Saint-Etienne, France
700    1_
$a Ollier, Edouard $u Unité de Recherche Clinique, Innovation et Pharmacologie, CHU de Saint-Etienne, Saint-Etienne, France
700    1_
$a Zeitouni, Michel $u Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire, Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, Paris 75013, France
700    1_
$a Kerneis, Mathieu $u Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire, Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, Paris 75013, France $1 https://orcid.org/0000000271415209
700    1_
$a Procopi, Niki $u Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire, Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, Paris 75013, France $1 https://orcid.org/0000000177000744
700    1_
$a Barthelemy, Olivier $u Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire, Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, Paris 75013, France $1 https://orcid.org/000000027795094X
700    1_
$a Sorrentino, Sabato $u Division of Cardiology, Department of Medical and Surgical Science, Magna Graecia University, Catanzaro, Italy
700    1_
$a Mihalovic, Michal $u Cardiocenter, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Silvain, Johanne $u Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire, Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, Paris 75013, France
700    1_
$a Vicaut, Eric $u Unité de Recherche Clinique, Lariboisière Hospital (AP-HP), ACTION Study Group, Paris, France
700    1_
$a Montalescot, Gilles $u Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire, Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, Paris 75013, France $1 https://orcid.org/0000000308246809 $7 xx0108206
700    1_
$a Collet, Jean-Philippe $u Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire, Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, Paris 75013, France $1 https://orcid.org/0000000337505347
773    0_
$w MED00195025 $t European heart journal. Cardiovascular pharmacotherapy $x 2055-6845 $g Roč. 9, č. 3 (2023), s. 251-261
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36640149 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132433 $b ABA008
999    __
$a ok $b bmc $g 1963092 $s 1196729
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 9 $c 3 $d 251-261 $e 2023Apr10 $i 2055-6845 $m European heart journal. Cardiovascular pharmacotherapy $n Eur Heart J Cardiovasc Pharmacother $x MED00195025
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace